Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14842133 | 0.86 | SLC29A1 (0.58) | ADORA2AADORA2BADORA1 | |
| SCHEMBL1274810 | 0.85 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1CYP2C19 | |
| SCHEMBL1707366 | 0.85 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1CYP2C19 | |
| SCHEMBL1274809 | 0.85 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1CYP2C19 | |
| SCHEMBL29389281 | 0.85 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1CYP2C19 | |
| SCHEMBL29882584 | 0.81 | KDM4E (0.51) | KDM4EPKMADORA2AADORA3ADORA1 | |
| SCHEMBL29278767 | 0.81 | ADORA3 (0.59) | KDM4EPKMADORA2AADORA3ADORA1 | |
| SCHEMBL31490447 | 0.81 | KDM4E (0.54) | KDM4EPKMADORA2AADORA3ADORA1 | |
| SCHEMBL6765506 | 0.80 | ADORA3 (0.49) | KDM4EPKMADORA2AADORA2BADORA3 | |
| SCHEMBL28894183 | 0.80 | ADORA3 (0.54) | KDM4EPKMADORA3ADORA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| US-12042527-B2 | Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers | MODERNATX, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12037616-B2 | Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions | CRISPR THERAPEUTICS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037583-B2 | Compositions and methods for immunooncology | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| WO-2013096709-A2 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013090186-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090648-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-6727059-B1 | ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | KDM4E 2620/4885PKM 1199/4885ADORA2A 1186/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | KDM4E 4143/4885PKM 4798/4885ADORA2A 3850/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | KDM4E 4406/4885PKM 2355/4885ADORA2A 244/4885 |
| US-12042527-B2 | Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers | IL36G, IL23R, CD274 | KDM4E 2417/4885PKM 2822/4885ADORA2A 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.